NASDAQ:NKTR Nektar Therapeutics - NKTR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. $0.93 -0.05 (-5.10%) (As of 03/20/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.92▼$1.0150-Day Range$0.93▼$3.1552-Week Range$0.92▼$6.40Volume8.54 million shsAverage Volume3.60 million shsMarket Capitalization$176.24 millionP/E RatioN/ADividend YieldN/APrice Target$3.08 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Nektar Therapeutics MarketRank™ ForecastAnalyst RatingHold1.50 Rating ScoreUpside/Downside231.1% Upside$3.08 Price TargetShort InterestHealthy4.62% of Shares Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment0.87Based on 7 Articles This WeekInsider TradingSelling Shares$121,158 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.40 out of 5 starsMedical Sector195th out of 988 stocksPharmaceutical Preparations Industry75th out of 482 stocks 2.8 Analyst's Opinion Consensus RatingNektar Therapeutics has received a consensus rating of Hold. The company's average rating score is 1.50, and is based on no buy ratings, 3 hold ratings, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.08, Nektar Therapeutics has a forecasted upside of 231.1% from its current price of $0.93.Amount of Analyst CoverageNektar Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.62% of the outstanding shares of Nektar Therapeutics have been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Nektar Therapeutics has recently decreased by 11.79%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNektar Therapeutics does not currently pay a dividend.Dividend GrowthNektar Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNektar Therapeutics has received a 60.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topoisomerase 1 (TOP1) inhibitors", "Clinical research services", and "Peripheral opioid receptor antagonists" products. See details.Environmental SustainabilityThe Environmental Impact score for Nektar Therapeutics is -1.77. Previous Next 3.8 News and Social Media Coverage News SentimentNektar Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Nektar Therapeutics this week, compared to 2 articles on an average week.Search Interest18 people have searched for NKTR on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $121,158.00 in company stock.Percentage Held by InsidersOnly 3.38% of the stock of Nektar Therapeutics is held by insiders.Percentage Held by Institutions92.30% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nektar Therapeutics are expected to remain at ($0.89) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nektar Therapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nektar Therapeutics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNektar Therapeutics has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nektar Therapeutics (NASDAQ:NKTR) StockNektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.Read More Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTR Stock News HeadlinesMarch 15, 2023 | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Sees Significant Decline in Short InterestMarch 14, 2023 | finance.yahoo.comSage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock?March 21, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 6, 2023 | markets.businessinsider.comAnalyst Ratings for Nektar TherapeuticsMarch 6, 2023 | msn.comNektar Therapeutics Earnings Perspective: Return On Capital EmployedFebruary 28, 2023 | msn.comNektar Therapeutics GAAP EPS of -$0.32 beats by $0.13, revenue of $22.02M misses by $0.19MFebruary 26, 2023 | seekingalpha.comNektar Therapeutics: Another Clinical Failure Nearly Wipes Out The R&D ValueFebruary 25, 2023 | seekingalpha.comNektar Therapeutics plunges 29% after hours on mid-stage lupus treatment failureMarch 21, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. February 24, 2023 | investorplace.comWhy Is Nektar Therapeutics (NKTR) Stock Down 39% Today?February 24, 2023 | msn.comNektar Plunges after Topline Data Misses Primary EndpointFebruary 24, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Vapotherm (VAPO) and Nektar Therapeutics (NKTR)February 23, 2023 | finance.yahoo.comNektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus ErythematosusFebruary 23, 2023 | reuters.comNektar Therapeutics' autoimmune disease drug fails mid-stage studyFebruary 18, 2023 | seekingalpha.comNektar Therapeutics Looking To Rebuild Faith In Its Now Early-Stage PipelineFebruary 1, 2023 | technews.tmcnet.comGlancy Prongay & Murray LLP Announces Investigation of Nektar Therapeutics (NKTR)January 4, 2023 | finance.yahoo.comNektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CADecember 23, 2022 | reuters.comNKTR.O - Nektar Therapeutics | Stock Price & Latest News | ReutersDecember 13, 2022 | markets.businessinsider.comMizuho Securities Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)December 12, 2022 | finance.yahoo.comNektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual MeetingNovember 18, 2022 | seekingalpha.comNektar Therapeutics: Recovery Seems To Be A MirageNovember 10, 2022 | finance.yahoo.comNektar Therapeutics Third Quarter 2022 Earnings: Beats ExpectationsNovember 10, 2022 | finance.yahoo.comNektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 10, 2022 | markets.businessinsider.comSVB Securities Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)November 9, 2022 | finance.yahoo.comNektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell ImmunotherapyNovember 4, 2022 | finance.yahoo.comNektar's (NKTR) Q3 Earnings and Revenues Beat EstimatesNovember 4, 2022 | markets.businessinsider.comNektar Therapeutics Q3 Loss decreases, beats estimatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTR Company Calendar Last Earnings2/28/2023Today3/20/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:NKTR CUSIP64026810 CIK906709 Webwww.nektar.com Phone(415) 482-5300Fax415-339-5300Employees740Year Founded1990Price Target and Rating Average Stock Price Forecast$3.08 High Stock Price Forecast$6.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+231.1%Consensus RatingHold Rating Score (0-4)1.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-368,200,000.00 Net Margins-399.98% Pretax Margin-396.48% Return on Equity-76.92% Return on Assets-42.03% Debt Debt-to-Equity RatioN/A Current Ratio8.00 Quick Ratio7.72 Sales & Book Value Annual Sales$92.06 million Price / Sales1.91 Cash FlowN/A Price / Cash FlowN/A Book Value$1.95 per share Price / Book0.48Miscellaneous Outstanding Shares189,240,000Free Float182,839,000Market Cap$176.24 million OptionableOptionable Beta1.10 Social Links Key ExecutivesHoward W. RobinPresident, Chief Executive Officer & DirectorJillian B. ThomsenChief Financial Officer & Senior Vice PresidentJonathan ZalevskyChief Research & Development OfficerBrian L. KotzinChief Medical Officer & Senior Vice PresidentMary TagliaferriChief Development Officer & Senior Vice PresidentKey CompetitorsOmerosNASDAQ:OMERParatek PharmaceuticalsNASDAQ:PRTKAssembly BiosciencesNASDAQ:ASMBGeneration BioNASDAQ:GBIOSelecta BiosciencesNASDAQ:SELBView All CompetitorsInsiders & InstitutionsVoya Investment Management LLCBought 44,817 shares on 2/28/2023Ownership: 0.134%Howard W RobinSold 19,635 sharesTotal: $58,905.00 ($3.00/share)Alliancebernstein L.P.Sold 765,596 shares on 2/16/2023Ownership: 0.252%Jillian B ThomsenSold 10,267 sharesTotal: $30,801.00 ($3.00/share)Jonathan ZalevskySold 10,484 sharesTotal: $31,452.00 ($3.00/share)View All Insider TransactionsView All Institutional Transactions NKTR Stock - Frequently Asked Questions Should I buy or sell Nektar Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 3 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares. View NKTR analyst ratings or view top-rated stocks. What is Nektar Therapeutics' stock price forecast for 2023? 6 brokerages have issued 12-month target prices for Nektar Therapeutics' shares. Their NKTR share price forecasts range from $1.50 to $6.00. On average, they predict the company's share price to reach $3.08 in the next twelve months. This suggests a possible upside of 231.1% from the stock's current price. View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts. How have NKTR shares performed in 2023? Nektar Therapeutics' stock was trading at $2.26 at the beginning of 2023. Since then, NKTR shares have decreased by 58.8% and is now trading at $0.9313. View the best growth stocks for 2023 here. Are investors shorting Nektar Therapeutics? Nektar Therapeutics saw a decline in short interest during the month of February. As of February 28th, there was short interest totaling 8,750,000 shares, a decline of 11.8% from the February 13th total of 9,920,000 shares. Based on an average trading volume of 1,960,000 shares, the short-interest ratio is currently 4.5 days. View Nektar Therapeutics' Short Interest. When is Nektar Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our NKTR earnings forecast. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings data on Tuesday, February, 28th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. The biopharmaceutical company had revenue of $22.02 million for the quarter, compared to the consensus estimate of $22.21 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 76.92% and a negative net margin of 399.98%. The business's revenue was down 11.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.79) EPS. What ETFs hold Nektar Therapeutics' stock? ETFs with the largest weight of Nektar Therapeutics (NASDAQ:NKTR) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco Nasdaq Future Gen 200 ETF (QQQS), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB).AdvisorShares Dorsey Wright Short ETF (DWSH) and What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO? 46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees. What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY). What is Nektar Therapeutics' stock symbol? Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR." Who are Nektar Therapeutics' major shareholders? Nektar Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (1.83%), Dimensional Fund Advisors LP (1.36%), Norges Bank (0.90%), Morgan Stanley (0.87%), Charles Schwab Investment Management Inc. (0.73%) and Principal Financial Group Inc. (0.63%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, R Scott Greer and Robert Chess. View institutional ownership trends. How do I buy shares of Nektar Therapeutics? Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nektar Therapeutics' stock price today? One share of NKTR stock can currently be purchased for approximately $0.93. How much money does Nektar Therapeutics make? Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $176.24 million and generates $92.06 million in revenue each year. The biopharmaceutical company earns $-368,200,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. How many employees does Nektar Therapeutics have? The company employs 740 workers across the globe. How can I contact Nektar Therapeutics? Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300. This page (NASDAQ:NKTR) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.